Clinical Trial Update: Study to Assess the Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of EVP-6308 and the Potential of EVP-6308 to Affect the PK Properties of the Antipsychotic Regimen in Subjects With Schizophrenia Currently Receiving Stable Treatment With up to 2 Atypical Antipsychotics [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, tolerability, PK and PD of EVP-6308 and its potential to affect the PK of concomitant antipsychotic therapy in adults with schi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• EVP-6308

Snippet

Sponsor: FORUM Pharmaceuticals Inc | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED